Vitamin D and Zinc for COVID-19 patients
Not Applicable
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: B338- Other specified viral diseases
- Registration Number
- CTRI/2021/04/032593
- Lead Sponsor
- niversity Health Network
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 181
Inclusion Criteria
Men or women aged more than or equals to 18 years old, RTPCR confirmed infection with SARS-COV2,oxygen saturation level of 90 or above, and provide informed consent
Exclusion Criteria
Pregnancy, participants enrolled in other clinical trials, and daily use of multivitamins for the past 1 month
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the effect of vitamin D supplementation versus placebo on time to recovery among patients hospitalized with COVID-19; and to determine the effect of zinc supplementation versus placebo on time to recovery among patients hospitalized with COVID-19.Timepoint: Time point: Up to 8 weeks
- Secondary Outcome Measures
Name Time Method To determine the effect of vitamin D or zinc supplementation on time all-cause mortality; necessity for assisted ventilation; individual symptoms duration, and to examine additional co-morbidity and other determinants of severe outcomes of COVID-19.Timepoint: Time Point : 8 weeks